Pregabalin vs placebo
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
- no estimate extracted5 studies · 1874 participantsHigh
Findings
What do systematic reviews say?
36 questions · 36 findings · 20 reviews
No studies found 2 · 5.6%GRADE not reported 2 · 5.6%Very low 18 · 50%Low 10 · 27.8%Moderate 1 · 2.8%High 3 · 8.3%
Intravenous preparations vs oral preparations
Withdrawals due to adverse events · IBD patients
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 0.39 [0.2, 0.74]5 studies · 927 participantsLow
Antidepressants vs placebo
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
Antidepressant showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antidepressants for functional abdominal pain disorders in children and adolescents 2021 · Cochrane Headline outcomes onlyRR 3.17 [0.65, 15.33]3 studies · 238 participantsLow
Prebiotic vs probiotic
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with probiotics (very low certainty).
1 finding from 1 review
- Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes onlyRR 1 [0.44, 2.26]1 study · 80 participantsVery low
Prebiotic vs synbiotics
Withdrawals due to adverse events · people in remission or with mildly activeulcerative colitis
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
1 finding from 1 review
- Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes onlyRR 1.13 [0.48, 2.62]1 study · 80 participantsVery low
Prebiotic vs placebo
Withdrawals due to adverse events · people with histologically confirmed diagnosis of ulcerative colitis in remission
It is very uncertain whether prebiotics changes withdrawals due to adverse events (60 days to 6 months) compared with placebo (very low certainty).
1 finding from 1 review
- Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes onlyRR 2.57 [1.15, 5.73]2 studies · 125 participantsVery low
Prebiotic vs placebo
Withdrawals due to adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes withdrawals due to adverse events (14 days to 2 or 3 months) compared with placebo (very low certainty).
1 finding from 1 review
- Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes onlyRR 2.73 [0.51, 14.55]2 studies · 31 participantsVery low
Prebiotics and anti‐inflammatory therapy vs anti‐inflammatory therapy
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
- Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pregabalin vs placebo at end of treatment
Withdrawals due to adverse events · patients with fibromyalgia
Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).
1 finding from 1 review
- RR 1.68 [1.36, 2.07]5 studies · 3259 participantsHigh
Pregabalin vs placebo
Withdrawals due to adverse events · children and adolescents with chronic non‐cancer pain
1 finding from 1 review
- Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 107 participantsVery low
Tricyclic antidepressants vs control
Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis
It is very uncertain whether tricyclic antidepressant changes number of Withdrawals due to Adverse Events patient interview compared with control (very low certainty).
1 finding from 1 review
- RR 0.98 [0.59, 1.64]6 studies · 455 participantsVery low
Prefabricated foot orthoses vs shoes
Withdrawals due to adverse events · children with asymptomatic flat feet
It is very uncertain whether prefabricated foot orthoses changes withdrawal due to adverse events compared with shoes (very low certainty).
1 finding from 1 review
- RR 0.99 [0.79, 1.23]Studies not reportedVery low
Prefabricated foot orthoses vs shoes
Withdrawals due to adverse events · children with juvenile idiopathic arthritis and flat feet
Prefabricated foot orthoses showed no clear difference in withdrawal due to adverse events compared with shoes; GRADE not reported.
1 finding from 1 review
- RR 0.72 [0.14, 3.61]Studies not reportedGRADE not reported
Prefabricated foot orthoses vs shoes
Withdrawals due to adverse events · children with symptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Drospirenone plus ethinylestradiol vs placebo
Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))
Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral contraceptives containing drospirenone for premenstrual syndrome 2023 · Cochrane Headline outcomes onlyOR 3.41 [2.01, 5.78]4 studies · 776 participantsLow
Usual care vs immunosuppressive withdrawal after monotherapy
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
- Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 2.59 [0.35, 19.04]2 studies · 135 participantsVery low
SSRIs or SNRIs vs other antidepressants
Withdrawals due to adverse events · patients with tension‐type headache
SSRIs or SNRIs showed no clear difference in withdrawals due to adverse events compared with other antidepressants (low certainty).
1 finding from 1 review
- Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes onlyOR 1.04 [0.41, 2.6]4 studies · 257 participantsLow
Selective serotonin reuptake inhibitors vs placebo
Withdrawals due to adverse events · adult men with premature ejaculation
SSRI may leads to higher study withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men 2021 · Cochrane Headline outcomes onlyRR 3.8 [2.61, 5.51]20 studies · 7367 participantsLow
Oestrogen in combination with progestogen (sequential or continuous) vs placebo
Withdrawals due to adverse events · women with PMS
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
1 finding from 1 review
- Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes onlyRR 0.64 [0.26, 1.58]3 studies · 196 participantsVery low
Custom foot orthoses vs prefabricated foot orthoses
Withdrawals due to adverse events · children with asymptomatic flat feet
Custom foot orthoses showed no clear difference in withdrawal due to adverse events compared with prefabricated foot orthoses (low certainty).
1 finding from 1 review
- RR 1 [0.9, 1.12]Studies not reportedLow